G1 Therapeutics, Inc. (Nasdaq: GTHX) to Ring The Nasdaq Stock Market Closing Bell
August 01 2017 - 10:00AM
What: G1 Therapeutics, Inc. (Nasdaq:GTHX),
a clinical-stage biopharmaceutical company developing novel,
small-molecule therapies that address significant unmet needs in
the treatment of cancer, will visit the Nasdaq MarketSite in Times
Square.
In honor of the occasion, Mark Velleca, Chief Executive
Officer, will ring the Closing Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Wednesday, August 2, 2017 – 3:45 p.m. to
4:00 p.m. ET
G1 Therapeutics, Inc. Contact:
Investors:Robert UhlWestwicke Partners(858)
356-5932robert.uhl@westwicke.com
Media:Laura
Bagby
6 Degrees Communications(312) 448-8098lbagby@6degreespr.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About G1 Therapeutics, Inc.G1 Therapeutics
(GTHX) is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel therapeutics for the treatment
of cancer. G1’s two clinical assets, trilaciclib and G1T38, are
CDK4/6 inhibitors, a validated and promising class of targets for
anti-cancer therapeutics. Trilaciclib and G1T38 have broad
therapeutic potential in many forms of cancer and may serve as the
backbone of multiple combination regimens. In addition, G1 is
advancing G1T48, a potential first/best-in-class oral selective
estrogen receptor degrader, or SERD, which is targeted for the
treatment of ER+ breast cancer.
G1 is based in Research Triangle Park, NC. For additional
information about G1, please visit www.g1therapeutics.com.
About Nasdaq:Nasdaq (Nasdaq:NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 90
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to 3,800 total listings with a market
value of $11 trillion. To learn more, visit:
http://business.nasdaq.com
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024
